{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T04:16:16Z","timestamp":1778040976727,"version":"3.51.4"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015993","name":"Kowa Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015993","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.exer.2025.110351","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T04:24:19Z","timestamp":1742444659000},"page":"110351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Ripasudil does not induce phospholipid accumulation in human corneal epithelial cells"],"prefix":"10.1016","volume":"255","author":[{"given":"Fumiko","family":"Tazoe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuho","family":"Kanazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kasano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiro","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exer.2025.110351_bib1","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1194\/jlr.M900008-JLR200","article-title":"The role of negatively charged lipids in lysosomal phospholipase A2 function","volume":"50","author":"Abe","year":"2009","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.exer.2025.110351_bib2","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/13543776.2019.1670812","article-title":"Rho-kinase inhibitors in the management of glaucoma","volume":"29","author":"Berrino","year":"2019","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.exer.2025.110351_bib3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1515\/hsz-2019-0270","article-title":"Emerging mechanisms of drug-induced phospholipidosis","volume":"401","author":"Breiden","year":"2020","journal-title":"Biol. Chem."},{"key":"10.1016\/j.exer.2025.110351_bib4","first-page":"71","article-title":"American Academy of Ophthalmology Preferred Practice Pattern Glaucoma Panel","volume":"128","author":"Gedde","year":"2021","journal-title":"Primary Open-Angle Glaucoma Preferred Practice Pattern\u00ae Ophthalmology"},{"key":"10.1016\/j.exer.2025.110351_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.preteyeres.2013.05.002","article-title":"Rho-associated kinase inhibitors: a novel glaucoma therapy","volume":"37","author":"Inoue","year":"2013","journal-title":"Prog. Retin. Eye Res."},{"key":"10.1016\/j.exer.2025.110351_bib6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1089\/jop.2016.0028","article-title":"Ocular penetration and pharmacokinetics of ripasudil following topical administration to rabbits","volume":"32","author":"Isobe","year":"2016","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.exer.2025.110351_bib7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ajo.2019.01.003","article-title":"Long-term safety and ocular hypotensive efficacy evaluation of netarsudil ophthalmic solution: Rho kinase elevated IOP treatment trial (ROCKET-2)","volume":"200","author":"Kahook","year":"2019","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.exer.2025.110351_bib8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/toxsci\/kfj067","article-title":"Establishment of an in vitro high-throughput screening assay for detecting phospholipidosis-inducing potential","volume":"90","author":"Kasahara","year":"2006","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.exer.2025.110351_bib9","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s10384-022-00970-9","article-title":"The Japan Glaucoma Society guidelines for glaucoma 5th edition","volume":"67","author":"Kiuchi","year":"2023","journal-title":"Jpn. J. Ophthalmol."},{"key":"10.1016\/j.exer.2025.110351_bib10","first-page":"6125","article-title":"Evaluation of the potential of AR-13324 and AR-13503 to induce phospholipidosis","volume":"59","author":"Lin","year":"2018","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2025.110351_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1293\/tox.21.9","article-title":"Drug-induced phospholipidosis -pathological aspects and its prediction","volume":"21","author":"Nonoyama","year":"2008","journal-title":"J. Toxicol. Pathol."},{"key":"10.1016\/j.exer.2025.110351_bib12","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.survophthal.2016.11.008","article-title":"Drug-induced corneal epithelial changes","volume":"62","author":"Raizman","year":"2017","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.exer.2025.110351_bib13","doi-asserted-by":"crossref","DOI":"10.1001\/jamaophthalmol.2023.2949","article-title":"Symptomatic netarsudil-induced verticillata","volume":"141","author":"Rivera","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.exer.2025.110351_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2021-000943","article-title":"Drug-induced corneal deposits: an up-to-date review","volume":"7","author":"Sahyoun","year":"2022","journal-title":"BMJ Open Ophthalmol"},{"key":"10.1016\/j.exer.2025.110351_bib15","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ajo.2017.11.019","article-title":"Two phase 3 clinical trials comparing the safety and efficacy of netarsudil to timolol in patients with elevated intraocular pressure: Rho kinase elevated IOP treatment trial 1 and 2 (ROCKET-1 and ROCKET-2)","volume":"186","author":"Serle","year":"2018","journal-title":"Am. J. Ophthalmol."},{"key":"10.1016\/j.exer.2025.110351_bib16","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1111\/aos.12829","article-title":"One-year clinical evaluation of 0.4% ripasudil (K-115) in patients with open-angle glaucoma and ocular hypertension","volume":"94","author":"Tanihara","year":"2016","journal-title":"Acta Ophthalmol."},{"key":"10.1016\/j.exer.2025.110351_bib17","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1007\/s12325-021-02023-y","article-title":"Long-term intraocular pressure-lowering effects and adverse events of ripasudil in patients with glaucoma or ocular hypertension over 24 months","volume":"39","author":"Tanihara","year":"2022","journal-title":"Adv. Ther."}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483525001228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483525001228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T04:06:55Z","timestamp":1778040415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483525001228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":17,"alternative-id":["S0014483525001228"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2025.110351","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ripasudil does not induce phospholipid accumulation in human corneal epithelial cells","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2025.110351","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110351"}}